1. Home
  2. IHRT vs ADCT Comparison

IHRT vs ADCT Comparison

Compare IHRT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iHeartMedia Inc.

IHRT

iHeartMedia Inc.

HOLD

Current Price

$3.92

Market Cap

623.2M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.66

Market Cap

483.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHRT
ADCT
Founded
1974
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
623.2M
483.1M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
IHRT
ADCT
Price
$3.92
$3.66
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$4.50
$7.60
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
02-26-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,856,033,000.00
$75,209,000.00
Revenue This Year
$1.96
$10.36
Revenue Next Year
$5.62
$3.87
P/E Ratio
N/A
N/A
Revenue Growth
1.39
6.35
52 Week Low
$0.95
$1.05
52 Week High
$5.44
$4.80

Technical Indicators

Market Signals
Indicator
IHRT
ADCT
Relative Strength Index (RSI) 42.14 47.55
Support Level $4.31 $3.38
Resistance Level $4.28 $3.66
Average True Range (ATR) 0.21 0.20
MACD -0.08 0.01
Stochastic Oscillator 4.13 45.39

Price Performance

Historical Comparison
IHRT
ADCT

About IHRT iHeartMedia Inc.

iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: